Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

[Good practices for the surveillance and control of antimicrobial resistance].

Moro ML, Ciofi Degli Atti M, D'Amore C, Diegoli G, Forni S, Gagliotti C, Gemmi F, Iannazzo S, Miraglia V, Pan A, Pantosti A, Pitatlis S, Puro V, Ricchizzi E, Sarnelli B, Torti C, Zotti C.

Epidemiol Prev. 2019 Mar-Jun;43(2-3):185-193. doi: 10.19191/EP19.2-3.P185.058. Italian.

2.

The law on compulsory vaccination in Italy: an update 2 years after the introduction.

D'Ancona F, D'Amario C, Maraglino F, Rezza G, Iannazzo S.

Euro Surveill. 2019 Jun;24(26). doi: 10.2807/1560-7917.ES.2019.24.26.1900371.

3.

Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.

Hirt C, Iannazzo S, Chiroli S, McGarry LJ, le Coutre P, Stenke L, Dahlén T, Lipton JH.

Appl Health Econ Health Policy. 2019 Aug;17(4):555-567. doi: 10.1007/s40258-019-00489-0.

PMID:
31168745
4.

[ESCULAPIO: A project to elaborate strategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in the population].

Bechini A, Bonanni P, Moscadelli A, Lauri S, Tiscione E, Levi M, Prato R, Fortunato F, Martinelli D, Gasparini R, Panatto D, Amicizia D, Coppola RC, Pellizzari B, Tabacchi G, Costantino C, Casuccio A, Vitale F, Iannazzo S, Boccalini S.

Epidemiol Prev. 2019 Jan-Feb;43(1):71-75. doi: 10.19191/EP19.1.P71.023. Italian.

5.

Polio and measles: reasons of missed vaccination in Italy, 2015-2017.

Gianfredi V, D'Ancona F, Maraglino F, Cenci C, Iannazzo S.

Ann Ig. 2019 May-Jun;31(3):191-201. doi: 10.7416/ai.2019.2282.

6.

Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.

Cortesi PA, Barca R, Giudicatti G, Mossini S, Ciaccio A, Iannazzo S, Micale M, Cesana G, Mantovani LG.

Aliment Pharmacol Ther. 2019 May;49(9):1126-1133. doi: 10.1111/apt.15201. Epub 2019 Mar 6. Review.

PMID:
30843268
7.

Bloodstream infections due to carbapenemase-producing Enterobacteriaceae in Italy: results from nationwide surveillance, 2014 to 2017.

Iacchini S, Sabbatucci M, Gagliotti C, Rossolini GM, Moro ML, Iannazzo S, D'Ancona F, Pezzotti P, Pantosti A.

Euro Surveill. 2019 Jan;24(5). doi: 10.2807/1560-7917.ES.2019.24.5.1800159.

8.

Regional reports for the subnational monitoring of measles elimination in Italy and the identification of local barriers to the attainment of the elimination goal.

Adamo G, Sturabotti G, Baccolini V, de Soccio P, Prencipe GP, Bella A, Magurano F, Iannazzo S, Villari P, Marzuillo C.

PLoS One. 2018 Oct 24;13(10):e0205147. doi: 10.1371/journal.pone.0205147. eCollection 2018.

9.

Interconnected clusters of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11), involving bisexuals and men who have sex with men, with discos and gay-venues hotspots of transmission, Tuscany, Italy, 2015 to 2016.

Miglietta A, Fazio C, Neri A, Pezzotti P, Innocenti F, Azzari C, Rossolini GM, Moriondo M, Nieddu F, Iannazzo S, D'Ancona F, Maraglino FP, Guerra R, Rezza G, Voller F, Stefanelli P.

Euro Surveill. 2018 Aug;23(34). doi: 10.2807/1560-7917.ES.2018.23.34.1700636.

10.

Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

Levy MY, McGarry LJ, Huang H, Lustgarten S, Chiroli S, Iannazzo S.

Curr Med Res Opin. 2019 Mar;35(3):479-487. doi: 10.1080/03007995.2018.1510225. Epub 2018 Aug 24.

PMID:
30086654
11.

Childhood vaccine coverage in Italy after the new law on mandatory immunization.

Signorelli C, Odone A, Cella P, Iannazzo S.

Ann Ig. 2018 Jul-Aug;30(4 Supple 1):1-10. doi: 10.7416/ai.2018.2227.

12.

An outbreak of severe invasive meningococcal disease due to a capsular switched Neisseria meningitidis hypervirulent strain B:cc11.

Stefanelli P, Fazio C, Vacca P, Palmieri A, Ambrosio L, Neri A, Piana A, Castiglia P, Argiolas F, Santus S, Masala L, Steri G, Riccardo F, Iannazzo S, Maraglino FP, D'Amario C, Rezza G.

Clin Microbiol Infect. 2019 Jan;25(1):111.e1-111.e4. doi: 10.1016/j.cmi.2018.07.014. Epub 2018 Jul 21.

13.

Introduction of new and reinforcement of existing compulsory vaccinations in Italy: first evaluation of the impact on vaccination coverage in 2017.

D'Ancona F, D'Amario C, Maraglino F, Rezza G, Ricciardi W, Iannazzo S.

Euro Surveill. 2018 May;23(22). doi: 10.2807/1560-7917.ES.2018.23.22.1800238.

14.

The GISA call to action for the appropriate use of antimicrobials and the control of antimicrobial resistance in Italy.

Menichetti F, Falcone M, Lopalco P, Tascini C, Pan A, Busani L, Viaggi B, Rossolini GM, Arena F, Novelli A, De Rosa F, Iannazzo S, Cohen J; for GISA (Italian Group for Antimicrobial Stewardship).

Int J Antimicrob Agents. 2018 Aug;52(2):127-134. doi: 10.1016/j.ijantimicag.2018.05.010. Epub 2018 May 24.

PMID:
29802887
15.

Using Routine Data Sources to Feed an Immunization Information System for High-Risk Patients-A Pilot Study.

Martinelli D, Fortunato F, Iannazzo S, Cappelli MG, Prato R.

Front Public Health. 2018 Feb 16;6:37. doi: 10.3389/fpubh.2018.00037. eCollection 2018.

16.

Immunisation Registries at regional level in Italy and the roadmap for a future Italian National Registry.

D'Ancona F, Gianfredi V, Riccardo F, Iannazzo S.

Ann Ig. 2018 Mar-Apr;30(2):77-85. doi: 10.7416/ai.2018.2199.

17.

[The elimination of measles and rubella in Italy].

Adamo G, Sturabotti G, De Soccio P, Prencipe GP, Sciarra I, Baccolini V, Massimi A, Marzuillo C, Iannazzo S, Villari P.

Ig Sanita Pubbl. 2017 Sep-Oct;73(5):429-442. Italian.

PMID:
29433130
18.

A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.

Stollenwerk B, Iannazzo S, Akehurst R, Adena M, Briggs A, Dehmel B, Parfrey P, Belozeroff V.

Pharmacoeconomics. 2018 May;36(5):603-612. doi: 10.1007/s40273-017-0605-2.

PMID:
29392552
19.

Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.

Iannazzo S, Benucci M, Favalli EG.

Clin Exp Rheumatol. 2018 May-Jun;36(3):479-485. Epub 2018 Jan 15.

PMID:
29352843
20.

The imperative of vaccination put into practice.

Signorelli C, Iannazzo S, Odone A.

Lancet Infect Dis. 2018 Jan;18(1):26-27. doi: 10.1016/S1473-3099(17)30696-5. Epub 2017 Dec 20. No abstract available.

PMID:
29303734
21.

Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.

Iannazzo S, Iliza AC, Perrault L.

Pharmacoeconomics. 2018 Feb;36(2):189-204. doi: 10.1007/s40273-017-0577-2.

PMID:
29032493
22.

Infant immunization coverage in Italy (2000-2016).

Signorelli C, Odone A, Cella P, Iannazzo S, D'Ancona F, Guerra R.

Ann Ist Super Sanita. 2017 Jul-Sep;53(3):231-237. doi: 10.4415/ANN_17_03_09.

23.

Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.

Stollenwerk B, Iannazzo S, Cooper K, Belozeroff V.

J Med Econ. 2017 Oct;20(10):1110-1115. doi: 10.1080/13696998.2017.1360309. Epub 2017 Aug 14.

PMID:
28803497
24.

Towards measles elimination in Italy: Virological surveillance and genotypes trend (2013-2015).

Magurano F, Baggieri M, Filia A, Del Manso M, Lazzarotto T, Amendola A, D'Agaro P, Chironna M, Ansaldi F, Iannazzo S, Bucci P, Marchi A, Nicoletti L; Measles Surveillance Group.

Virus Res. 2017 May 15;236:24-29. doi: 10.1016/j.virusres.2017.05.009. Epub 2017 May 15.

PMID:
28522332
25.

Strategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in the population: The ESCULAPIO project.

Bechini A, Bonanni P, Lauri S, Tiscione E, Levi M, Prato R, Fortunato F, Martinelli D, Gasparini R, Panatto D, Amicizia D, Coppola RC, Pellizzari B, Tabacchi G, Costantino C, Vitale F, Iannazzo S, Boccalini S.

Hum Vaccin Immunother. 2017 Feb;13(2):369-375. doi: 10.1080/21645515.2017.1268008.

26.

A large prolonged outbreak of hepatitis A associated with consumption of frozen berries, Italy, 2013-14.

Scavia G, Alfonsi V, Taffon S, Escher M, Bruni R, Medici D, Pasquale SD, Guizzardi S, Cappelletti B, Iannazzo S, Losio NM, Pavoni E, Decastelli L, Ciccaglione AR, Equestre M, Tosti ME, Rizzo C, National Italian Task Force On Hepatitis A.

J Med Microbiol. 2017 Mar;66(3):342-349. doi: 10.1099/jmm.0.000433. Epub 2017 Mar 23.

PMID:
28086079
27.

The end of measles and congenital rubella: an achievable dream?

Adamo G, Sturabotti G, D'Andrea E, Baccolini V, Romano F, Iannazzo S, Marzuillo C, Villari P.

Ann Ig. 2017 Jan-Feb;29(1):1-26. doi: 10.7416/ai.2017.2128. Review.

28.

Cost of persistent asthma in Italy.

Dal Negro RW, Distante C, Bonadiman L, Turco P, Iannazzo S.

Multidiscip Respir Med. 2016 Dec 16;11:44. doi: 10.1186/s40248-016-0080-1. eCollection 2016.

29.

Clinical and economic impact of herpes zoster vaccination in elderly in Italy.

Boccalini S, Alicino C, Martinelli D, Bechini A, Tiscione E, Pellizzari B, Prato R, Icardi G, Iannazzo S, Bonanni P.

Hum Vaccin Immunother. 2017 Feb;13(2):405-411. doi: 10.1080/21645515.2017.1264832. Epub 2016 Dec 7.

30.

Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study.

Alicino C, Trucchi C, Paganino C, Barberis I, Boccalini S, Martinelli D, Pellizzari B, Bechini A, Orsi A, Bonanni P, Prato R, Iannazzo S, Icardi G.

Hum Vaccin Immunother. 2017 Feb;13(2):399-404. doi: 10.1080/21645515.2017.1264834. Epub 2016 Dec 7.

31.

Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A.

Iannazzo S, Cortesi PA, Crea R, Steinitz K, Mantovani LG, Gringeri A.

Blood Coagul Fibrinolysis. 2017 Sep;28(6):425-430. doi: 10.1097/MBC.0000000000000610.

PMID:
27898515
32.

The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database.

Iannazzo S, Furneri G, Demma F, Distante C, Parisi S, Berti V, Fusaro E.

Rheumatol Ther. 2016 Jun;3(1):167-177. doi: 10.1007/s40744-016-0034-2. Epub 2016 May 26.

33.

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.

Paolicelli D, Iannazzo S, Santoni L, Iaffaldano A, Di Lecce V, Manni A, Lavolpe V, Tortorella C, D'Onghia M, Direnzo V, Puma E, Trojano M.

PLoS One. 2016 Jul 8;11(7):e0159214. doi: 10.1371/journal.pone.0159214. eCollection 2016.

34.

Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma.

Dal Negro RW, Distante C, Bonadiman L, Turco P, Iannazzo S.

Multidiscip Respir Med. 2016 Jun 6;11:20. doi: 10.1186/s40248-016-0055-2. eCollection 2016.

35.

Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012-2013).

Palazzo R, Carollo M, Fedele G, Rizzo C, Rota MC, Giammanco A, Iannazzo S, Ausiello CM, Sero-Epidemiology Working Group.

J Med Microbiol. 2016 Jul;65(7):649-657. doi: 10.1099/jmm.0.000264. Epub 2016 Apr 13.

PMID:
27075481
36.

Increased incidence of invasive meningococcal disease of serogroup C / clonal complex 11, Tuscany, Italy, 2015 to 2016.

Stefanelli P, Miglietta A, Pezzotti P, Fazio C, Neri A, Vacca P, Voller F, D'Ancona FP, Guerra R, Iannazzo S, Pompa MG, Rezza G.

Euro Surveill. 2016;21(12). doi: 10.2807/1560-7917.ES.2016.21.12.30176.

37.

Vaccine coverage in Italy and assessment of the 2012-2014 National Immunization Prevention Plan.

Bonanni P, Ferro A, Guerra R, Iannazzo S, Odone A, Pompa MG, Rizzuto E, Signorelli C.

Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):146-58.

38.

Invasive pneumococcal disease in children and adults in seven Italian regions after the introduction of the conjugate vaccine, 2008-2014.

D'Ancona F, Caporali MG, Del Manso M, Giambi C, Camilli R, D'Ambrosio F, Del Grosso M, Iannazzo S, Rizzuto E, Pantosti A.

Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):134-8.

39.

Measles in Italy: Co-circulation of B3 variants during 2014.

Magurano F, Baggieri M, Bordi L, Lalle E, Chironna M, Lazzarotto T, Amendola A, Baldanti F, Ansaldi F, Filia A, Declich S, Iannazzo S, Pompa MG, Bucci P, Marchi A, Nicoletti L.

J Med Virol. 2016 Jun;88(6):1081-5. doi: 10.1002/jmv.24416. Epub 2015 Nov 6.

PMID:
26496509
40.

Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy.

Gaultney J, Benucci M, Iannazzo S, Nappi C, Sion K, Sabater FJ.

Expert Rev Pharmacoecon Outcomes Res. 2016 Jun;16(3):409-17. doi: 10.1586/14737167.2016.1102636. Epub 2015 Oct 23.

PMID:
26495961
41.

Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update.

Dal Negro RW, Bonadiman L, Turco P, Tognella S, Iannazzo S.

Clinicoecon Outcomes Res. 2015 Mar 16;7:153-9. doi: 10.2147/CEOR.S77504. eCollection 2015.

42.

[Polio vaccination failure in Italy, years 2006-2010].

Iannazzo S, Rizzuto E, Pompa MG.

Epidemiol Prev. 2014 Nov-Dec;38(6 Suppl 2):98-102. Italian.

43.

A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C.

Iannazzo S, Colombatto P, Ricco G, Oliveri F, Bonino F, Brunetto MR.

Dig Liver Dis. 2015 Mar;47(3):249-54. doi: 10.1016/j.dld.2014.12.008. Epub 2014 Dec 18.

PMID:
25575431
44.

Measles in Italy, laboratory surveillance activity during 2010.

Fortuna C, Baggieri M, Marchi A, Benedetti E, Bucci P, Del Manso M, Declich S, Iannazzo S, Pompa MG, Nicoletti L, Magurano F.

Ann Ist Super Sanita. 2014;50(4):341-4. doi: 10.4415/ANN_14_04_08.

45.

[Improving vaccination measures].

Iannazzo S.

Ann Ig. 2014 May-Jun;26(3 Suppl 1):53-5. Italian.

PMID:
25486692
46.

Cost-Effectiveness Analysis Of A Personalized Therapy For Genotype 1, Naive, Chronic Hepatitis C Patients In Italy.

Iannazzo S, Colombatto P, Bonino F, Brunetto MR.

Value Health. 2014 Nov;17(7):A366. doi: 10.1016/j.jval.2014.08.819. Epub 2014 Oct 26. No abstract available.

47.

Epidemiology of pertussis in Italy: disease trends over the last century.

Gonfiantini MV, Carloni E, Gesualdo F, Pandolfi E, Agricola E, Rizzuto E, Iannazzo S, Ciofi Degli Atti ML, Villani A, Tozzi AE.

Euro Surveill. 2014 Oct 9;19(40):20921. Review.

48.

Economic evaluation of intravenous iodinated contrast media in Italy.

Iannazzo S, Vandekerckhove S, De Francesco M, Nayak A, Ronco C, Morana G, Valentino M.

Int J Technol Assess Health Care. 2014 Jan;30(1):69-77. doi: 10.1017/S0266462313000706. Epub 2014 Jan 31. Erratum in: Int J Technol Assess Health Care. 2014 Jul;30(3):341.

PMID:
24485022
49.

A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.

Iannazzo S, De Francesco M, Gomez-Ulloa D, Benucci M.

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):455-68. doi: 10.1586/14737167.2013.814937. Review.

PMID:
23977974
50.

Analysis of national measles surveillance data in Italy from October 2010 to December 2011 and priorities for reaching the 2015 measles elimination goal.

Filia A, Bella A, Rota M, Tavilla A, Magurano F, Baggieri M, Nicoletti L, Iannazzo S, Pompa M, Declich S.

Euro Surveill. 2013 May 16;18(20). pii: 20480.

Supplemental Content

Loading ...
Support Center